Amendments to the Specification:

1. Page 1, before line 5, but after the title, insert the following:

---BACKGROUND OF THE INVENTION

1. Field of the Invention---;

2. Page 1, before line 8, insert the following:

---2. Discussion of Background Information---;

3. Please replace the paragraph at page 1, lines 8-15 by the following amended paragraph:

Customary cosmetic application forms and preparations are often emulsions. This term is generally understood as meaning a heterogeneous system of two liquids which are immiscible or miscible only to a limited extent with one another and are usually referred to as phases. One is in the form of droplets (disperse or internal phase), whilst the other liquid forms a continuous (coherent or internal) phase[[ )]]. Less common application forms are multiple emulsions, i.e. those which, in the droplets of the dispersed (or discontinuous) phase, comprise for their part droplets of a further dispersed phase, e.g. W/O/W emulsions and O/W/O emulsions.

4. Page 3, after line 7, insert and center the following:

---SUMMARY OF THE INVENTION---;

5. Please replace the passage from page 3, line 9, to page 4, line 4 from the top, by the following new paragraphs:

---The present invention provides a first cosmetic or dermatological composition which comprises:

(I) up to 10 % by weight, based on a total weight of the composition, of one or more C_{12}-C_{40} fatty acids,

(II) from 0.1 % to 10 % by weight, based on a total weight of the composition, of one or more C_{12}-C_{40} fatty alcohols,

(III) from 0.01 % to 10 % by weight, based on a total weight of the composition, of at least one of an amphiphilic polymer, an associative polymer and a siloxane elastomer,

(IV) at least one of sodium hydroxide and potassium hydroxide,

(V) from 0.1 % to 10 % by weight, based on a total weight of the composition, of one or more C_{12}-C_{40} polyethoxylated fatty acid esters having a polyethoxy chain length of from 10 to 100,

(VI) optionally, at least one low molecular weight surfactant, and

(VII) from 0.1 % to 30 % by weight of at least one of a pigment and a dye.

The present invention also provides a second cosmetic or dermatological composition which comprises:

(I) up to 12 % by weight, based on a total weight of the composition, of one or more C_{12}-C_{40} fatty acids,

(II) from 0 % to 3 % by weight, based on a total weight of the composition, of one or more C_{12}-C_{40} fatty alcohols,

(III) from 0.01 % to 10 % by weight, based on a total weight of the composition, of at least one of an amphiphilic polymer, an associative polymer and a siloxane elastomer,

(IV) at least one of sodium hydroxide and potassium hydroxide, and

(VII) from 0.1 % to 30 % by weight of at least one of a pigment and a dye.

In one aspect of the above compositions, component (I) may comprise stearic acid and/or palmitic acid, and/or component (II) may comprise one or more of myristyl alcohol, cetyl alcohol, behenyl alcohol, stearyl alcohol and cetearyl alcohol, and/or component (III) may comprise one or more of dimethicone/vinyl dimethicone crosspolymer, polysilicone–11, acrylate/C_{10-30} alkyl acrylate crosspolymer, acrylate/vinyl isodecanoate crosspolymer, acrylate/steareth–20 methacrylate copolymer, acrylate/steareth–20 itaconate copolymer, acrylate/steareth-50 acrylate copolymer, acrylate/palmeth-25 acrylate copolymer, steareth-10 allyl ether/acrylate copolymer, PEG-120 methylglucose dioleate, PEG-60 sorbitan tetraoleate, PEG-150 pentaerythrityl tetrastearate, PEG-55 propylene glycol oleate, PEG-150 distearate and PEG-180/laureth-50 TMMG copolymer, and/or component (IV) may comprise sodium hydroxide and/or component (VII) may comprise one or more of coated mica particles, TiO_2 particles, Fe_2O_3 particles, zinc oxide-coated SiO_2 particles, iron pearlescent pigments prepared without the use of mica and aluminum pearlescent pigments.

In another aspect of the first composition, component (V) may comprise PEG-30 stearate, PEG-40 stearate and/or PEG-100 stearate.

In yet another aspect of the first composition, component (VI) may comprise steareth-2, laureth-4 and/or ceteth-3, preferably at least laureth-4.

In a still further aspect of the first composition, the ratio (I) : (II) : (V) may be from 5 : 1 : 1 to

1 : 1 : 5, e.g., from 3 : 1 : 1 to 3 : 1 : 3, or from 3 : 1 : 1 to 1 : 1 : 3.

In another aspect of the above compositions, component (VII) may be present in an amount of from 0.5 % to 15 % by weight, e.g., from 1.0 % to 5.0 % by weight.

In yet another aspect of the above compositions, component (I) may be present in an amount of from 0.1 % to 10 % by weight.

In another aspect of the first composition, component (II) may be present in an amount of from 0.1 % to 5 % by weight, e.g., in an amount of up to 3 % by weight, and/or component (V) may be present in an amount of up to 5 % by weight.

In a still further aspect of the first and second compositions of the present invention, these compositions may comprise from 0.01 % to 5 % by weight of an amphiphilic polymer and/or an associative polymer, for example, 0.1 % to 1 % by weight thereof. Alternatively or cumulatively, these compositions may comprise at least 0.5 % by weight of a siloxane elastomer.

In another aspect of the first composition, the composition may comprise:

(I) up to 10 % by weight of stearic acid and/or palmitic acid,

(II) from 0.1 % to 10 % by weight of one or more of cetyl alcohol, behenyl alcohol, stearyl alcohol and cetearyl alcohol,

(III) from 0.01 % to 10 % by weight of one or more of dimethicone/vinyl dimethicone

crosspolymer, polysilicone-11, acrylate/alkyl acrylate crosspolymer, acrylate/vinyl isodecanoate crosspolymer, acrylate/steareth–20 methacrylate copolymer, acrylate/steareth–20 itaconate copolymer, acrylate/steareth-50 acrylate copolymer, acrylate/palmeth-25 acrylate copolymer, steareth-10 allyl ether/acrylate copolymer, PEG-120 methylglucose dioleate, PEG-60 sorbitan tetraoleate, PEG-150 pentaerythrityl tetrastearate, PEG-55 propylene glycol oleate, PEG-150 distearate and PEG-180/laureth-50/TMMG copolymer,

(IV) from 0.15 % to 1 % by weight of sodium hydroxide,

(V) up to 10 % by weight of one or more of PEG-20 stearate, PEG-40 stearate and PEG-100 stearate,

(VI) from 0 % to 10 % by weight of one or more of steareth-2, laureth-4 and ceteth-3, and

(VII) from 1.0 % to 5.0 % by weight of a pigment and/or a dye.

In another aspect of the second composition, the composition may comprise:

(I) up to 12 % by weight of stearic acid and/or palmitic acid,

(II) from 0 % to 3 % by weight of one or more of cetyl alcohol, behenyl alcohol, stearyl alcohol and cetearyl alcohol,

(III) from 0.01 % to 10 % by weight of one or more of dimethicone/vinyl dimethicone crosspolymer, polysilicone-11, acrylate/alkyl acrylate crosspolymer, acrylate/vinyl isodecanoate crosspolymer, acrylate/steareth–20 methacrylate copolymer, acrylate/steareth–20 itaconate copolymer, acrylate/steareth-50 acrylate copolymer, acrylate/palmeth-25 acrylate copolymer, steareth-10 allyl ether/acrylate copolymer, PEG-120 methylglucose dioleate, PEG-60 sorbitan tetraoleate, PEG-150 pentaerythrityl tetrastearate, PEG-55 propylene glycol oleate, PEG-150 distearate and PEG-180/laureth-50/TMMG copolymer,

(IV) 0.25 % to 1 % by weight of sodium hydroxide, and

(VII) from 1.0 % to 5.0 % by weight of at least one of a pigment and a dye.

In yet another aspect of the present compositions, the compositions may comprise sodium

hydroxide as the only neutralizing agent.

In a still further aspect of the present compositions, not more than 9 % of the one or more fatty acids may be saponified.

In another aspect, the present compositions may further comprise up to 30 % by weight of a non-polar lipid having a polarity of at least 30 mN/m, a mineral oil, a silicone oil and/or a wax. The non-polar lipid and the wax may be selected from non-polar hydrocarbons, hydrogenated polyisobutene, squalane, cyclomethicones, dimethicones, methyl palmitate and dimethiconol stearate. Still further, the lipid phase of the composition may comprise up to 60 % by weight, based on the total weight of the lipid phase, of one or more polar lipids having a polarity of at most 30 mN/m.

In yet another aspect, the compositions of the present invention may further comprise a solubilizer, e.g., PEG-40 hydrogenated castor oil, and/or the compositions may further comprise a photoprotective filter, a moisturizer, an active ingredient, a powder raw material, a preservative, a filler and/or a deodorant.

In a still further aspect, the compositions may further comprise ethanol in an amount of up to 30 % by weight.

The present invention also provides a decorative cosmetic product, a skin care product, a

photoprotective product, and a cleansing emulsion, all of which comprise one of the compositions of the present invention.---;

6. Please replace the paragraph at page 15, lines 2-3 by the following amended paragraph:

Quaternized cationic cellulose with at least one fatty acid group, such as alkyl, arylalkyl or alkylaryl groups ~~groups~~ or mixtures thereof, preferably with a carbon number of C8-C22.

7. Please replace the paragraph from page 24, line 19 to page 25, line 19 by the following amended paragraph:

The further emulsifier(s) is/are advantageously chosen from the group which comprises the following compounds:
polyglyceryl-2 dipolyhydroxystearate, PEG-30 dipolyhydroxystearate, cetyldimethicone copolyol, glycol distearate, glycol dilaurate, diethylene glycoldilaurate, sorbitan trioleate, glycol oleate, glyceryl dilaurate, sorbitan tristearate, propylene glycol stearate, propylene glycol laurate, propylene glycol distearate, sucrose distearate, PEG-3 castor oil, pentaerythrityl monostearate, pentaerythrityl sesquioleate, glyceryl oleate, pentaerythrityl monooleate, sorbitan sesquioleate, isostearyl diglyceryl succinate, glyceryl caprate, palm glycerides, cholesterol, lanolin, glyceryl oleate (with 40% monoester), polyglyceryl-2 sesquiisostearate, polyglyceryl-2 sesquioleate, PEG-20 sorbitan beeswax, sorbitan oleate, sorbitan isostearate, trioleyl phosphate, glyceryl stearate and ceteareth-20 (Teginacid from Th. Goldschmidt), sorbitan stearate, PEG-7 hydrogenated castor oil, PEG-5 soy sterol, PEG-6 sorbitan beeswax, methylglucose sesquistearates, PEG-10 hydrogenated castor oil, sorbitan palmitate, PEG-22/dodecyl glycol copolymer, polyglyceryl-2 PEG-4 stearate, sorbitan laurate, PEG-4 laurate, polysorbate 61, polysorbate 81, polysorbate 65, polysorbate 80, tricetеareth-4 phosphate,

~~triceteareth-4 phosphate,~~ and sodium C_{14-17} alkyl sec sulphonate (Hostacerin CG from Hoechst), polysorbate 85, trilaureth-4 phosphate, PEG-35 castor oil, sucrose stearate, trioleth-8 phosphate, C_{12-15} pareth-12, PEG-40 hydrogenated castor oil, PEG-16 soy sterol, ~~polysorbate 80,~~ polysorbate 20, polyglyceryl-3 methylglucose distearate, PEG-40 castor oil, sodium cetearyl sulphate, lecithin, laureth-4 phosphate, propylene glycol stearate SE, PEG-25 hydrogenated castor oil, PEG-54 hydrogenated castor oil, PEG-6 caprylic/capric glycerides, glyceryl oleate and propylene glycol, polysorbate 60, polyglyceryl-3 oleate, PEG-40 sorbitan peroleate, laureth-4, isostearyl glyceryl ether, cetearyl alcohol and sodium cetearyl sulphate, PEG-22 dodecyl glycol copolymer, polyglyceryl-2 PEG-4 stearate, pentaerythrityl isostearate, polyglyceryl-3 diisostearate, sorbitan oleate and hydrogenated castor oil and Cera alba and stearic acid, sodium dihydroxycetyl phosphate and isopropyl hydroxycetyl ether, methylglucose sesquistearate, methylglucose dioleate, sorbitan oleate and PEG-2 hydrogenated castor oil and ozokerite and hydrogenated castor oil, PEG-2 hydrogenated castor oil, PEG-45/dodecyl glycol copolymer, methoxy PEG-22/dodecyl glycol copolymer, hydrogenated cocoglycerides, polyglyceryl-4 isostearate, PEG-40 sorbitan peroleate, PEG-40 sorbitan perisostearate, PEG-8 beeswax, laurylmethicone copolyol, polyglyceryl-2 laurate, stearamidopropyl PG dimonium chloride phosphate, PEG-7 hydrogenated castor oil, triethyl citrate, glyceryl stearate citrate, cetyl phosphate, polyglycerol methylglucose distearate, poloxamer 101, potassium cetyl phosphate, polyglyceryl-3 diisostearates and/or AbilCare 85 from Dow Corning.

8. Please replace the paragraph at page 36, lines 1-7 by the following amended paragraph:

The titanium dioxide pigments may be present either in the crystal modification rutile, or else in the form of anatase and may, for the purposes of the present invention, be advantageously surface-treated ("coated"), the intention being to form or retain, for example, a hydrophilic, amphiphilic or hydrophobic character. This surface treatment can involve providing the pigments with a thin hydrophilic and/or hydrophobic inorganic and/or organic layer by processes known per se. The various surface ~~coating~~ coatings can also comprise water for the purposes of the present invention.

9. Please replace the paragraph from page 47, line 25 to page 48, line 5 by the following amended paragraph:

Advantageous preservatives for the purposes of the present invention are, for example, formaldehyde donors (such as, for example, DMDM hydantoin, which is available, for example, under the trade name Glydant™ from Lonza), ~~iodopropyl~~ iodopropynyl butylcarbamates (e.g. those available under the trade names Glycacil-L, Glycacil-S from Lonza and/or Dekaben LMB from Jan Dekker), parabens (i.e. alkyl p-hydroxybenzoates, such as methyl-, ethyl-, propyl- and/or butylparaben), phenoxyethanol, ethanol, benzoic acid and the like. Usually, the preservative system according to the invention further advantageously also comprises preservative assistants, such as, for example, octoxyglycerol, glycine soya, etc. This list of advantageous preservatives should in no way be limiting. Instead, all preservatives approved for cosmetics or foods are advantageous for the purposes of the present invention.

10. Please replace the paragraph from page 49, line 32 to page 50, line 5 by the following amended paragraph:

It is in some cases possible and advantageous to use the preparations according to the invention as bases for pharmaceutical formulations. Corresponding requirements apply mutatis mutandis to the formulation of medicinal preparations. The transitions between pure cosmetics and pure pharmaceuticals are fluid here. Suitable pharmaceutical active ingredients according to the invention are in principle all classes of active ingredient, preference being given to lipophilic active ingredients. Examples are: antihistamines, antiphlogistics, antibiotics, antimycotics, active ingredients which promote circulation, keratolytics, ~~antihistamines, antiphlogistics, antibiotics, antimycotics, active ingredients which promote circulation, keratolytics,~~ hormones, steroids, vitamins, etc.

11. Page 51, after line 5, insert and center the following:

---DETAILED DESCRIPTION OF THE INVENTION---;

12. Page 59, first line, please change "**Patent claims**" to ---WHAT IS CLAIMED IS:---.